The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Abactal     1-ethyl-6-fluoro-7-(4- methylpiperazin-1...

Synonyms: Labocton, Peflacine, Pefloxacin, PERFLOXACIN, Pefloxacine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Pefloxacine


Psychiatry related information on Pefloxacine


High impact information on Pefloxacine


Chemical compound and disease context of Pefloxacine


Biological context of Pefloxacine

  • The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05) [15].
  • The relative bioavailability of pefloxacin after the antacid treatment was 44.4% +/- 23.8%, compared with that after a single administration [16].
  • Effects on oral and intestinal microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients [17].
  • Our results indicate that ofloxacin and pefloxacin do not induce inhibition of myelopoiesis [18].
  • Data from mainly non-comparative studies suggest that pefloxacin has the potential for use in a variety of serious or difficult-to-treat and nosocomially acquired infections in hospitalised and immunocompromised patients [19].

Anatomical context of Pefloxacine


Associations of Pefloxacine with other chemical compounds


Gene context of Pefloxacine

  • We therefore further characterized the interaction between pefloxacin and CYP1A2 [20].
  • The behavioral and convulsant effects of pefloxacin (PEFLO), a quinolone derivative, were studied after intraperitoneal (i.p.) administration to Dilute Brown Agouti DBA/2J (DBA/2) mice, a strain genetically susceptible to sound-induced seizures [28].
  • No inhibitory activity against purified IL-1 or IL-2 could be demonstrated in the dialyzed supernatants from pefloxacin- or ciprofloxacin-treated monocytes [29].
  • Neither pefloxacin nor ciprofloxacin modified the biological activity of preformed IL-1 [29].
  • Moreover, IL-2, a known mediator of apoptosis was found to be downregulated, whereas TNF-alpha had been upregulated for the first 18 hours after pefloxacin administration [30].

Analytical, diagnostic and therapeutic context of Pefloxacine

  • Comparison of plasma and dialysate concentrations of pefloxacin after intravenous, oral, or intraperitoneal administration shows excellent bidirectional diffusion of the quinolone through the peritoneal membrane, demonstrating that therapeutical concentrations can be achieved in the dialysate after intravenous or oral administration [31].
  • The concentrations of pefloxacin and its metabolites in plasma and urine were determined by high-performance liquid chromatography assays [16].
  • Pefloxacin pharmacokinetics and serum bactericidal activities (SBA) against Escherichia coli and Staphylococcus aureus were compared after intravenous infusion of either a single 800-mg dose or twice-daily 400-mg doses into 16 healthy volunteers [32].
  • Clinical trials with pefloxacin in patients at risk for P. carinii pneumonia appear to be justified [33].
  • The results (expressed as mean log10 CFU per milliliter +/- standard deviation) showed that pefloxacin significantly (P < 0.001) reduced the bacterial counts (4.39 +/- 0.97) compared with those in control eyes (6.46 +/- 0.69) [34].


  1. Toxic reaction following treatment of typhoid fever with pefloxacin. Caumes, E., Katlama, C., Chapius, L., Danis, M., Gentilini, M. Lancet (1990) [Pubmed]
  2. Side-effects of pefloxacin in idiopathic nephrotic syndrome. Aigrain, E.J., Brun, P., Bennasr, S., Loirat, C. Lancet (1993) [Pubmed]
  3. Pefloxacin for falciparum malaria: only modest success. Deloron, P., Lepers, J.P., Raharimalala, L., Dubois, B., Coulanges, P., Pocidalo, J.J. Ann. Intern. Med. (1991) [Pubmed]
  4. Pefloxacin treatment of meningitis caused by gram-negative bacteria. Segev, S., Barzilai, A., Rosen, N., Joseph, G., Rubinstein, E. Arch. Intern. Med. (1989) [Pubmed]
  5. An acute psychotic disorder caused by pefloxacin: a case report. Hesslinger, B., Hellwig, B., Sester, U., Walden, J., Berger, M. Prog. Neuropsychopharmacol. Biol. Psychiatry (1996) [Pubmed]
  6. Respiratory infections: clinical experiences with the new quinolones. Davies, B.I., Maesen, F.P. Pharmaceutisch weekblad. Scientific edition. (1987) [Pubmed]
  7. Ocular delivery systems of pefloxacin mesylate. Bharath, S., Hiremath, S.R. Die Pharmazie. (1999) [Pubmed]
  8. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Giamarellou, H., Kolokythas, E., Petrikkos, G., Gazis, J., Aravantinos, D., Sfikakis, P. Am. J. Med. (1989) [Pubmed]
  9. Metabolism and the fluoroquinolones. Outman, W.R., Nightingale, C.H. Am. J. Med. (1989) [Pubmed]
  10. Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia. Chidiac, C., Roussel-Delvallez, M., Guery, B., Beaucaire, G. Antimicrob. Agents Chemother. (1995) [Pubmed]
  11. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Naber, K.G., Theuretzbacher, U., Kinzig, M., Savov, O., Sörgel, F. Antimicrob. Agents Chemother. (1998) [Pubmed]
  12. Systemic prophylaxis of experimental staphylococcal endophthalmitis: comparative efficacy of sparfloxacin, pefloxacin, imipenem, vancomycin, and amikacin. Marrakchi-Benjaafar, S., Cochereau, I., Pocidalo, J.J., Carbon, C. J. Infect. Dis. (1995) [Pubmed]
  13. Once-daily pefloxacin + teicoplanin vs netilmicin + teicoplanin in empirical therapy for fever and neutropenia. Studená, M., Hlavácová, E., Helpianska, L., Spanik, S., Lacka, J., Kukucková, E., Kollár, T., Sálek, T., Sufliarsky, J., Trupl, J. Drugs (1995) [Pubmed]
  14. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Dworkin, R., Modin, G., Kunz, S., Rich, R., Zak, O., Sande, M. Antimicrob. Agents Chemother. (1990) [Pubmed]
  15. Influence of rifampin on the pharmacokinetics of pefloxacin. Humbert, G., Brumpt, I., Montay, G., Le Liboux, A., Frydman, A., Borsa-Lebas, F., Moore, N. Clin. Pharmacol. Ther. (1991) [Pubmed]
  16. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Jaehde, U., Sörgel, F., Stephan, U., Schunack, W. Antimicrob. Agents Chemother. (1994) [Pubmed]
  17. Effects on oral and intestinal microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients. Giuliano, M., Pantosti, A., Gentile, G., Venditti, M., Arcese, W., Martino, P. Antimicrob. Agents Chemother. (1989) [Pubmed]
  18. Influence of two quinolones, ofloxacin and pefloxacin, on human myelopoiesis in vitro. Pallavicini, F., Antinori, A., Federico, G., Fantoni, M., Nervo, P. Antimicrob. Agents Chemother. (1989) [Pubmed]
  19. Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Gonzalez, J.P., Henwood, J.M. Drugs (1989) [Pubmed]
  20. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Kinzig-Schippers, M., Fuhr, U., Zaigler, M., Dammeyer, J., Rüsing, G., Labedzki, A., Bulitta, J., Sörgel, F. Clin. Pharmacol. Ther. (1999) [Pubmed]
  21. Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group. Jardin, A., Cesana, M. Antimicrob. Agents Chemother. (1995) [Pubmed]
  22. Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1. Rajagopalan-Levasseur, P., Dournon, E., Dameron, G., Vilde, J.L., Pocidalo, J.J. Antimicrob. Agents Chemother. (1990) [Pubmed]
  23. Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Simonin, M.A., Gegout-Pottie, P., Minn, A., Gillet, P., Netter, P., Terlain, B. Antimicrob. Agents Chemother. (2000) [Pubmed]
  24. Combination therapy: a way to limit emergence of resistance? Michéa-Hamzehpour, M., Pechère, J.C., Marchou, B., Auckenthaler, R. Am. J. Med. (1986) [Pubmed]
  25. Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni. Charvalos, E., Tselentis, Y., Hamzehpour, M.M., Köhler, T., Pechere, J.C. Antimicrob. Agents Chemother. (1995) [Pubmed]
  26. Comparative oral pharmacokinetics of fleroxacin and pefloxacin. De Lepeleire, I., Van Hecken, A., Verbesselt, R., Tjandra-Maga, T.B., De Schepper, P.J. J. Antimicrob. Chemother. (1988) [Pubmed]
  27. In-vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin. Van der Auwera, P., Grenier, P., Glupczynski, Y., Pierard, D. J. Antimicrob. Chemother. (1989) [Pubmed]
  28. Effects of some excitatory amino acid antagonists and drugs enhancing gamma-aminobutyric acid neurotransmission on pefloxacin-induced seizures in DBA/2 mice. De Sarro, G., Nava, F., Calapai, G., De Sarro, A. Antimicrob. Agents Chemother. (1997) [Pubmed]
  29. Effects of quinolones on interleukin 1 production in vitro by human monocytes. Roche, Y., Fay, M., Gougerot-Pocidalo, M.A. Immunopharmacology (1987) [Pubmed]
  30. Mitochondrial activity after cold preservation of pancreatic islet cells treated with pefloxacin (PFX). Puc, J., Kwiatkowski, P., Pacanowski, J., Rotbart-Fiedor, M., Wardawa, A., Mazurek, A.P., Rowinski, W., Hardy, M.A., Fiedor, P. Ann. Transplant. (1998) [Pubmed]
  31. Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis. Schmit, J.L., Hary, L., Bou, P., Renaud, H., Westeel, P.F., Andrejak, M., Fournier, A. Antimicrob. Agents Chemother. (1991) [Pubmed]
  32. Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers. Petitjean, O., Pangon, B., Brion, N., Tod, M., Chaplain, C., Le Gros, V., Louchahi, K., Allouch, P. Antimicrob. Agents Chemother. (1993) [Pubmed]
  33. Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia. Brun-Pascaud, M., Fay, M., Zhong, M., Bauchet, J., Dux-Guyot, A., Pocidalo, J.J. Antimicrob. Agents Chemother. (1992) [Pubmed]
  34. Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. Marrakchi-Benjaafar, S., Cochereau, I., D'Hermies, F., Pocidalo, J.J. Antimicrob. Agents Chemother. (1995) [Pubmed]
WikiGenes - Universities